Monitor the EHA presentations on June 13 for detailed efficacy/safety data, particularly lasme-cel response rates in post-CD19 CAR-T patients. The Q4 2026 interim analysis is the next major catalyst for lasme-cel. No immediate trading action warranted.
Price Chart
Executive Summary
Cellectis announced upcoming presentations of Phase 1 data for lasme-cel (BALLI-01) and eti-cel (NATHALI-01) at the EHA 2026 annual congress in June. The lasme-cel abstract was selected for an oral presentation, highlighting promising safety and response rates in heavily pretreated r/r B-ALL patients, and the pivotal Phase 2 trial is recruiting with interim data expected in Q4 2026. This is a routine clinical update with no new financial data or material changes to the company's outlook.
Key Facts
- Lasme-cel Phase 1 BALLI-01 data selected for oral presentation at EHA 2026 (June 11-14, Stockholm)
- Pivotal Phase 2 BALLI-01 trial recruiting; first interim analysis expected Q4 2026
- Eti-cel Phase 1 NATHALI-01 abstract accepted for poster presentation; Phase 1 data planned for Q4 2026
- No financial results, guidance, or material agreements disclosed
Financial Impact
No financial figures disclosed; pre-revenue clinical-stage biotech
Risk Factors
- Phase 1 data may not predict Phase 2 or registrational outcomes
- Competition from approved CD19 CAR-Ts and other allogeneic programs
- Cash runway and financing risk not addressed in this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-003280 |
| Document: f6k_051226.htm | 0001171843-26-003280 |
| Document: 0001171843-26-003280-index-headers.html | 0001171843-26-003280 |
| Document: 0001171843-26-003280-index.html | 0001171843-26-003280 |
| Document: 0001171843-26-003280.txt | 0001171843-26-003280 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 6w ago | 6-K | $1.83 | awaiting T+60 | — | $0.9901 (+45.90%) |
Sep 11, 2026 6w ago | Press Release | $1.83 | awaiting T+60 | — | $0.9901 (−45.90%) |
Aug 6, 2026 11w ago | Press Release | $2.84 | awaiting T+60 | — | $0.9901 (−65.08%) |
Jun 29, 2026 17w ago | Court Ruling | $3.00 $1.43 | ▼ −52.33% | ▼ −55.32% | $0.9901 (−67.00%) |
Jun 25, 2026 17w ago | 6-K | $2.83 $1.51 | ▼ −46.64% | ▼ −52.75% | $0.9901 (−65.01%) |
Jun 25, 2026 17w ago | 6-K | $2.83 $1.51 | ▼ −46.64% | ▼ −52.75% | $0.9901 (−65.01%) |
Jun 11, 2026 19w ago | Press Release | $3.09 $3.24 | ▲ +4.85% | ▲ +0.46% | $0.9901 (−67.96%) |
Jun 9, 2026 19w ago | 6-K | $3.18 $3.32 | ▲ +4.40% | ▼ −2.18% | $0.9901 (−68.86%) |
May 12, 2026 24w ago | 6-K | $3.96 $2.69 | ▼ −32.07% | ▼ −36.45% | $0.9901 (−75.00%) |
May 4, 2026 25w ago | 6-K | $3.76 $2.85 | ▼ −24.20% | ▼ −26.94% | $0.9901 (−73.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers